By vgreene, 8 September, 2020 28-day all-cause mortality: CS 33% vs SOC/placebo 41% (summary OR 0.66, 95% CI 0.53-0.82 based on fixed-effect analysis; summary OR 0.7, 95% CI 0.48-1.01; I2=15.6% based on random-effects
By vgreene, 8 September, 2020 Prospective meta-analysis incl. 7 RCTs (6 studies w/ low bias risk, 1 study w/ “some concerns” of bias); 1,703 hospitalized, critically ill pts (mean age 60y) w/ COVID-19 treated w/ CS (dexamethasone, hydrocortisone, or methylprednisolone) (n=678) or SOC/
